FY2026 Earnings Estimate for VRTX Issued By Erste Group Bank

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities researchers at Erste Group Bank cut their FY2026 earnings per share estimates for shares of Vertex Pharmaceuticals in a research note issued to investors on Wednesday, October 21st. Erste Group Bank analyst H. Engel now expects that the pharmaceutical company will post earnings of $16.65 per share for the year, down from their previous estimate of $16.68. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $16.75 per share. Erste Group Bank also issued estimates for Vertex Pharmaceuticals’ FY2027 earnings at $18.97 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.74 by ($0.01). Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. The business had revenue of $3.33 billion during the quarter, compared to analyst estimates of $3.23 billion. During the same quarter in the previous year, the firm posted $4.52 earnings per share. The firm’s quarterly revenue was up 12.5% on a year-over-year basis.

A number of other brokerages have also recently issued reports on VRTX. Canaccord Genuity Group upped their target price on Vertex Pharmaceuticals from $436.00 to $442.00 and gave the company a “hold” rating in a research report on Tuesday, August 4th. Cantor Fitzgerald increased their price target on Vertex Pharmaceuticals from $590.00 to $595.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Stifel Nicolaus set a $500.00 target price on Vertex Pharmaceuticals and gave the stock a “hold” rating in a report on Tuesday, August 4th. Sanford C. Bernstein upgraded Vertex Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, July 29th. Finally, Wall Street Zen raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, October 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $579.81.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX opened at $535.17 on Friday. Vertex Pharmaceuticals has a 52-week low of $403.16 and a 52-week high of $560.25. The stock has a market cap of $135.83 billion, a PE ratio of 31.15, a P/E/G ratio of 2.51 and a beta of 0.28. The firm has a 50-day moving average of $523.15 and a 200-day moving average of $482.96.

Hedge Funds Weigh In On Vertex Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of VRTX. Summit Global Investments bought a new stake in shares of Vertex Pharmaceuticals in the second quarter worth $3,568,000. Calamos Advisors LLC lifted its position in shares of Vertex Pharmaceuticals by 77.1% in the 1st quarter. Calamos Advisors LLC now owns 77,886 shares of the pharmaceutical company’s stock worth $34,779,000 after purchasing an additional 33,917 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. boosted its stake in shares of Vertex Pharmaceuticals by 11.9% in the 1st quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. now owns 34,991 shares of the pharmaceutical company’s stock valued at $15,625,000 after purchasing an additional 3,710 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab acquired a new stake in shares of Vertex Pharmaceuticals during the second quarter worth $13,823,000. Finally, UNIVEST FINANCIAL Corp bought a new position in Vertex Pharmaceuticals during the second quarter worth $4,495,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.